Business
Celularity Announces Closing of Financing Transactions
FLORHAM PARK, N.J., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company addressing age-related and degenerative diseases, today announced the closing of its previously disclosed financing transactions with Philip A. Barach, co-founder and former president of DoubleLine Capital LP. At the closing, Celularity received $10.00 million in gross proceeds. The transaction structure provides for the potential availability of up to
About this update from Celularity Inc.
[{"type":"text","content":"FLORHAM PARK, N.J., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company addressing age-related and degenerative diseases, today announced the closing of its previously disclosed financing transactions with Philip A. Barach, co-founder and former president of DoubleLine Capital LP.","length":355,"tagName":"p"},{"type":"text","content":"At the closing, Celularity received $10.00 million in gross proceeds. The transaction structure provides for the potential availability of up to an additional $2.0 million, subject to the satisfaction of specified closing conditions and the investor’s election, as set forth in the definitive agreements. The financing includes a senior secured term loan and a secured convertible note, and is intended to support Celularity’s ongoing operations and strategic initiatives.","length":472,"tagName":"p"},{"type":"text","content":"The senior secured term loan has a stated principal amount of $7.0 million and is secured by a first-priority lien on substantially all of Celularity’s assets, subject to certain customary exclusions and priority agreements. The secured convertible notes provide for aggregate commitments of up to $5.0 million, issuable in multiple tranches, and are convertible into shares of Celularity’s Class A common stock at a conversion price of $1.66 per share, subject to adjustment as set forth therein. The secured convertible notes are secured by a first-priority lien on proceeds from a qualified financing. In addition, Celularity issued five-year warrants to purchase an aggregate of 3,707,657 shares of Class A Common Stock to the investor which are exercisable beginning on June 19, 2026 and have an exercise price of $2.00 per share, subject to adjustment as set forth therein.","length":879,"tagName":"p"},{"type":"text","content":"“This closing strengthens Celularity’s financial position and provides meaningful flexibility as we continue to analyze and prioritize our platform and pipeline,” said Robert J. Hariri, M.D., Ph.D., Chairman and Chief Executive Officer of Celularity. “We appreciate Phil Barach’s long-term support and confidence in Celularity as we move forward.”","length":347,"tagName":"p"},{"type":"text","content":"Looking ahead, Celularity is increasingly focused on leveraging its placental-derived platfor...